Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 255-260

  Ebihara, Chiaki ^a   Kondoh, Masuo ^a   Hasuike, Naoki ^a   Harada, Motoki ^a   Mizuguchi, Hiroyuki ^b,c   Horiguchi, Yasuhiko ^b   Fujii, Makiko ^a   Watanabe, Yoshiteru ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BOVINE SERUM ALBUMIN; CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROXIN; HYBRID PROTEIN; PROTEIN INHIBITOR; PROTEIN SYNTHESIS INHIBITORY FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BAY REGION BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TARGET CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL SURVIVAL; CLOSTRIDIUM PERFRINGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENTEROTOXINS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; TRYPAN BLUE;

EID: 29244462966     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093351     Document Type: Article

References (40)

1. Allen TM and Cullis PR (2004) Drug delivery systems: entering the mainstream. Science (Wash DC) 303:1818-1822.
2. Beers R, Chowdhury P, Binger D, and Pastan I (2000) Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 6:2835-2843.
3. Bonifacino JS and Traub LM (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 72:395-447.
4. Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, et al. (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 46 (Suppl):S8-S12.
5. Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, and So S (2005) Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 11:551-556.
6. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, and Tsukita S (2000) Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 476:258-261.
7. Greenlee RT, Murray T, Bolden S, and Wingo PA (2000) Cancer Statistics, 2000 CA Cancer J Clin 50:7-33.
8. Hanna PC, Mietzner TA, Schoolnik GK, and McClane BA (1991) Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. J Biol Chem 266:11037-11043.
9. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, and Morin PJ (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60:6281-6287.
10. Ivanov AI, Nusrat A, and Parkos CA (2004) Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. Mol Biol Cell 15:176-188.
11. Katahira J, Inoue N, Horiguchi Y, Matsuda M, and Sugimoto N (1997) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 136:1239-1247.
12. Kondoh M, Masuyama A, Takahashi A, Asano N, Mizuguchi H, Koizumi N, Fujii M, Hayakawa T, Horiguchi Y, and Watanabe Y (2005) A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol Pharmacol 67:749-756.
13. Leamon CP, Pastan I, and Low PS (1993) Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. J Biol Chem 268:24847-24854.
14. Long H, Crean CD, Lee WH, Cummings OW, and Gabig TG (2001) Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61:7878-7881.
15. Masuyama A, Kondoh M, Seguchi H, Takahashi A, Harada M, Fujii M, Mizuguchi H, Horiguchi Y, and Watanabe Y (2005) Role of N-terminal amino acids in the absorption-enhancing effects of the C-terminal fragment of Clostridium perfringens enterotoxin. J Pharmacol Exp Ther 314:789-795.
16. Matsuda M, Kubo A, Furuse M, and Tsukita S (2004) A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. J Cell Sci 117:1247-1257.
17. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, et al. (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 6:1711-1719.
18. McClane BA and Chakrabarti G (2004) New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. Anaerobe 10:107-114.
19. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, and de Leij LF (2001) The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 61:4105-4111.
20. Mesri EA, Ono M, Kreitman RJ, Klagsbrun M, and Pastan I (1994) The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci 107:2599-2608.
21. Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Lohr M, et al. (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 63:6265-6271.
22. Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B, Tsukita S, Leder G, Adler G, and Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678-684.
23. Michl P and Gress TM (2004) Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr Cancer Drug Targets 4:689-702.
24. Morita K, Furuse M, Fujimoto K, and Tsukita S (1999a) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 96:511-516.
25. Morita K, Sasaki H, Furuse M, and Tsukita S (1999b) Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 147:185-194.
26. Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, and Kohleisen B (2005) Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immnunol Immunother 54:431-445.
27. Ogata M, Chaudhary VK, Pastan I, and FitzGerald DJ (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 265:20678-20685.
28. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, and Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567-2575.
29. Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, and Pecorelli S (2005) Treatment of chemotherapy-resistant human ovarian cancer xenografts in C. B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 65:4334-4342.
30. Schneeberger EE and Lynch RD (2004) The tight junction: a multifunctional complex. Am J Physiol 286:C1213-C1228.
31. Siegall CB, FitzGerald DJ, and Pastan I (1990) Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. J Biol Chem 265:16318-16323.
32. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, and Tsukita S (1999) Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 147:195-204.
33. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, et al. (1997) Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15:1529-1537.
34. Takahashi A, Kondoh M, Masuyama A, Fujii M, Mizuguchi H, Horiguchi Y, and Watanabe Y (2005) Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. J Control Release, in press.
35. Theuer CP, FitzGerald DJ, and Pastan I (1992) A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing. J Biol Chem 267:16872-16877.
36. Tsukita S, Furuse M, and Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285-293.
37. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, and Welsh MJ (2003) Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature (Lond) 422:322-326.
38. Wodarz A (2000) Tumor suppressors: linking cell polarity and growth control. Curr Biol 10:R624-R626.
39. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, et al. (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full activity. Nat Biotechnol 21:546-552.
40. Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137.